Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-803 (N-803) Plus BCG in Non-Muscle Invasive Bladder Cancer
2025-521223-78-00Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised trial of nogapendekin alfa inbakicept in bladder cancer (4 cohorts), sponsored by ImmunityBio, Inc. Started Aug 2025; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2025-521223-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521223-78-00.